Generate 50 HKMLE MCQs on Arrhythmias, Heart Block, and Cardiac Emergencies combined. Cover: AF, SVT, VT, Torsades, AV blocks (1st, Mobitz I/II, 3rd), BBB, cardiac arrest (VF/VT/asystole/PEA), acute pulmonary oedema, cardiogenic shock, tamponade. Short clinical vignettes with ECG descriptions. For each question: - Correct answer + 10-word explanation - One 10-word explanation for each distractor Format: Q#. [Short vignette] A) B) C) D) E) Answer: X — [10 words] Distractors: A) [10 words] B) [10 words] C) [10 words] D) [10 words] E) [10 words] Include HKMLE traps: adenosine in WPW+AF, atropine in Mobitz II, morphine in APO, IABP in CS, routine post-arrest PCI without STEMI. Base on Davidson's + 2024-2025 ESC/AHA guidelines. Now generate 50 MCQs.
Reading File
Finding Sources
Finding Sources
Searching the Web
ESC 2024 2025 guidelines atrial fibrillation VT cardiac arrest management updates
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
I now have sufficient reference material from Braunwald's, Goldman-Cecil, Fuster & Hurst, Tintinalli's, and Harrison's, plus 2024 ESC AF guideline context. I'll now generate all 50 MCQs comprehensively.
50 HKMLE MCQs: Arrhythmias, Heart Block & Cardiac Emergencies
Based on Davidson's Principles, Braunwald's Heart Disease, Goldman-Cecil Medicine, Fuster & Hurst's The Heart (15e), Tintinalli's Emergency Medicine, Harrison's (22e, 2025), and 2024 ESC AF / 2024 AHA Guidelines.
ATRIAL FIBRILLATION (Q1–10)
Q1. A 68-year-old man presents with 6 hours of palpitations and breathlessness. BP 130/80 mmHg, HR 145 bpm irregular. ECG shows no discernible P waves, irregularly irregular narrow QRS complexes. CHA₂DS₂-VA score is 3. Which is the most appropriate initial management?
A) Immediate DC cardioversion
B) IV amiodarone for rate control
C) IV metoprolol for rate control plus anticoagulation
D) Oral flecainide pill-in-pocket
E) Digoxin loading dose IV
B) IV amiodarone for rate control
C) IV metoprolol for rate control plus anticoagulation
D) Oral flecainide pill-in-pocket
E) Digoxin loading dose IV
Answer: C — Rate control and anticoagulation are first priority in haemodynamically stable AF.
Distractors:
A) DC cardioversion reserved for haemodynamically unstable patients only.
B) Amiodarone is rhythm control, not first-line rate control agent here.
D) Flecainide contraindicated without excluding structural/ischaemic heart disease first.
E) Digoxin is slow-acting, inferior to beta-blockers for acute rate control.
Distractors:
A) DC cardioversion reserved for haemodynamically unstable patients only.
B) Amiodarone is rhythm control, not first-line rate control agent here.
D) Flecainide contraindicated without excluding structural/ischaemic heart disease first.
E) Digoxin is slow-acting, inferior to beta-blockers for acute rate control.
Q2. A 55-year-old woman with known paroxysmal AF and no structural heart disease presents to ED. She is haemodynamically stable with AF of 30-hour duration. She has not been anticoagulated. What is the safest cardioversion strategy?
A) Immediate electrical cardioversion
B) TOE-guided cardioversion after confirming no LAA thrombus
C) Anticoagulate for 3–4 weeks, then cardioversion
D) Rate control only; no cardioversion
E) Chemical cardioversion with IV flecainide immediately
B) TOE-guided cardioversion after confirming no LAA thrombus
C) Anticoagulate for 3–4 weeks, then cardioversion
D) Rate control only; no cardioversion
E) Chemical cardioversion with IV flecainide immediately
Answer: B — TOE excludes LAA thrombus, allowing safe cardioversion when duration >48 h or unknown.
Distractors:
A) Cardioversion without anticoagulation or TOE risks thromboembolism after 48 hours.
C) Three-week anticoagulation applies when TOE unavailable, not mandatory if TOE performed.
D) Cardioversion is appropriate and desirable in symptomatic paroxysmal AF.
E) Chemical cardioversion without thrombus exclusion carries embolic risk after 48 hours.
Distractors:
A) Cardioversion without anticoagulation or TOE risks thromboembolism after 48 hours.
C) Three-week anticoagulation applies when TOE unavailable, not mandatory if TOE performed.
D) Cardioversion is appropriate and desirable in symptomatic paroxysmal AF.
E) Chemical cardioversion without thrombus exclusion carries embolic risk after 48 hours.
Q3. A 72-year-old man has AF. CHA₂DS₂-VA score is 4, HAS-BLED score is 1. He has no prior anticoagulation. Which anticoagulant is preferred per 2024 ESC guidelines?
A) Aspirin 75 mg daily
B) Warfarin with target INR 2–3
C) Apixaban 5 mg twice daily
D) Aspirin + clopidogrel dual antiplatelet
E) Dabigatran 75 mg twice daily
B) Warfarin with target INR 2–3
C) Apixaban 5 mg twice daily
D) Aspirin + clopidogrel dual antiplatelet
E) Dabigatran 75 mg twice daily
Answer: C — DOACs (apixaban) are first-line; superior to warfarin in non-valvular AF.
Distractors:
A) Aspirin does not significantly reduce stroke in AF and increases bleeding risk.
B) Warfarin is acceptable but DOACs preferred due to better safety/efficacy profile.
D) Dual antiplatelet is inferior to anticoagulation and not recommended for AF stroke prevention.
E) Dabigatran 75 mg is not a standard approved dose; 110 mg or 150 mg BD are standard.
Distractors:
A) Aspirin does not significantly reduce stroke in AF and increases bleeding risk.
B) Warfarin is acceptable but DOACs preferred due to better safety/efficacy profile.
D) Dual antiplatelet is inferior to anticoagulation and not recommended for AF stroke prevention.
E) Dabigatran 75 mg is not a standard approved dose; 110 mg or 150 mg BD are standard.
Q4. A 62-year-old woman with AF, LVEF 35%, and NYHA Class II heart failure is rate-controlled but remains symptomatic. She is on bisoprolol 10 mg daily. What is the most appropriate next step?
A) Add digoxin for additional rate control
B) Add verapamil for rate control
C) Refer for catheter ablation
D) Perform immediate DC cardioversion
E) Start amiodarone for rhythm control
B) Add verapamil for rate control
C) Refer for catheter ablation
D) Perform immediate DC cardioversion
E) Start amiodarone for rhythm control
Answer: C — 2024 ESC guidelines support early catheter ablation in AF with HFrEF to improve LVEF and outcomes.
Distractors:
A) Digoxin can be added but does not address tachycardia-mediated cardiomyopathy fundamentally.
B) Verapamil is contraindicated in HFrEF due to negative inotropy.
D) DC cardioversion alone without ablation has high AF recurrence in HFrEF.
E) Amiodarone is an option but ablation is preferred in HFrEF with symptomatic AF.
Distractors:
A) Digoxin can be added but does not address tachycardia-mediated cardiomyopathy fundamentally.
B) Verapamil is contraindicated in HFrEF due to negative inotropy.
D) DC cardioversion alone without ablation has high AF recurrence in HFrEF.
E) Amiodarone is an option but ablation is preferred in HFrEF with symptomatic AF.
Q5. A 58-year-old man presents with AF and rapid ventricular response. ECG shows irregularly irregular rhythm with broad, bizarre QRS complexes >200 bpm with delta waves. He is haemodynamically stable. What is the MOST dangerous drug to administer?
A) IV amiodarone
B) IV flecainide
C) IV adenosine
D) Synchronised DC cardioversion
E) IV procainamide
B) IV flecainide
C) IV adenosine
D) Synchronised DC cardioversion
E) IV procainamide
Answer: C — This is AF with WPW (pre-excited AF). Adenosine blocks the AV node, forcing all conduction down the accessory pathway, risking VF.
Distractors:
A) Amiodarone is relatively contraindicated but less immediately dangerous than AV nodal blockers.
B) Flecainide blocks accessory pathway conduction and is actually used for pre-excited AF.
D) DC cardioversion is the definitive safe treatment for haemodynamically significant pre-excited AF.
E) Procainamide is acceptable; it slows accessory pathway conduction without AV nodal block.
Distractors:
A) Amiodarone is relatively contraindicated but less immediately dangerous than AV nodal blockers.
B) Flecainide blocks accessory pathway conduction and is actually used for pre-excited AF.
D) DC cardioversion is the definitive safe treatment for haemodynamically significant pre-excited AF.
E) Procainamide is acceptable; it slows accessory pathway conduction without AV nodal block.
Q6. A 70-year-old man undergoes elective cardioversion for persistent AF. He is on apixaban 5 mg BD for 4 weeks. Post-cardioversion, how long should anticoagulation continue?
A) Stop anticoagulation immediately post-cardioversion
B) Continue for 4 weeks only
C) Continue for minimum 4 weeks, then reassess CHA₂DS₂-VA
D) Lifelong anticoagulation irrespective of CHA₂DS₂-VA score
E) Switch to aspirin after 4 weeks
B) Continue for 4 weeks only
C) Continue for minimum 4 weeks, then reassess CHA₂DS₂-VA
D) Lifelong anticoagulation irrespective of CHA₂DS₂-VA score
E) Switch to aspirin after 4 weeks
Answer: C — Post-cardioversion stunning risk for 4 weeks; then CHA₂DS₂-VA score guides ongoing therapy.
Distractors:
A) Cardioversion does not eliminate embolic risk; atrial stunning persists for weeks.
B) Four weeks covers stunning but ongoing anticoagulation depends on thromboembolic risk score.
D) Lifelong anticoagulation is indicated if CHA₂DS₂-VA ≥2 in males, ≥3 in females.
E) Aspirin is inadequate for AF stroke prevention regardless of post-cardioversion timing.
Distractors:
A) Cardioversion does not eliminate embolic risk; atrial stunning persists for weeks.
B) Four weeks covers stunning but ongoing anticoagulation depends on thromboembolic risk score.
D) Lifelong anticoagulation is indicated if CHA₂DS₂-VA ≥2 in males, ≥3 in females.
E) Aspirin is inadequate for AF stroke prevention regardless of post-cardioversion timing.
Q7. A 65-year-old woman with AF is noted to have a CHA₂DS₂-VA score of 1 (female sex only). Per 2024 ESC guidelines (which replaced CHA₂DS₂-VASc with CHA₂DS₂-VA), what is recommended?
A) Start anticoagulation immediately
B) Anticoagulation not recommended; reassess periodically
C) Start aspirin 75 mg daily
D) Start warfarin only
E) Refer for left atrial appendage closure
B) Anticoagulation not recommended; reassess periodically
C) Start aspirin 75 mg daily
D) Start warfarin only
E) Refer for left atrial appendage closure
Answer: B — CHA₂DS₂-VA score 0 in males or 1 in females (sex the only modifier) — anticoagulation not indicated; reassess annually.
Distractors:
A) Anticoagulation is only recommended when CHA₂DS₂-VA ≥2 (male) or adjusted female score.
C) Aspirin is not recommended for AF stroke prevention in 2024 ESC guidelines.
D) Warfarin is an anticoagulant and equally not indicated at this risk level.
E) LAAC is reserved for patients with contraindications to anticoagulation and higher risk.
Distractors:
A) Anticoagulation is only recommended when CHA₂DS₂-VA ≥2 (male) or adjusted female score.
C) Aspirin is not recommended for AF stroke prevention in 2024 ESC guidelines.
D) Warfarin is an anticoagulant and equally not indicated at this risk level.
E) LAAC is reserved for patients with contraindications to anticoagulation and higher risk.
Q8. A 75-year-old man with persistent AF and hypertension is found to have symptomatic AF despite rate control. He has structural heart disease (moderate LVH). Which antiarrhythmic is most appropriate for rhythm control?
A) Flecainide
B) Propafenone
C) Dronedarone
D) Amiodarone
E) Sotalol
B) Propafenone
C) Dronedarone
D) Amiodarone
E) Sotalol
Answer: D — Amiodarone is the only antiarrhythmic safe for rhythm control in significant structural heart disease.
Distractors:
A) Flecainide is contraindicated in structural heart disease due to pro-arrhythmic risk.
B) Propafenone is contraindicated in structural heart disease; similar risk to flecainide.
C) Dronedarone is contraindicated in permanent/persistent AF with structural heart disease.
E) Sotalol carries torsades risk with LVH; avoided in significant structural heart disease.
Distractors:
A) Flecainide is contraindicated in structural heart disease due to pro-arrhythmic risk.
B) Propafenone is contraindicated in structural heart disease; similar risk to flecainide.
C) Dronedarone is contraindicated in permanent/persistent AF with structural heart disease.
E) Sotalol carries torsades risk with LVH; avoided in significant structural heart disease.
Q9. A 60-year-old woman has a 3-day history of palpitations. ECG shows AF with ventricular rate 110 bpm. Echo shows LVEF 55%, no LVH. She scores CHA₂DS₂-VA of 2. She is keen to restore sinus rhythm. What rhythm control agent can be used safely?
A) Amiodarone alone
B) Flecainide
C) Digoxin
D) Verapamil
E) Sotalol first-line
B) Flecainide
C) Digoxin
D) Verapamil
E) Sotalol first-line
Answer: B — Flecainide is safe and effective for chemical cardioversion in AF without structural heart disease.
Distractors:
A) Amiodarone works but has significant adverse effect profile; not first-choice in structurally normal hearts.
C) Digoxin controls rate but does not cardiovert AF to sinus rhythm.
D) Verapamil does not cardiovert AF; it controls ventricular rate only.
E) Sotalol is not first-line for cardioversion; more used for maintenance of sinus rhythm.
Distractors:
A) Amiodarone works but has significant adverse effect profile; not first-choice in structurally normal hearts.
C) Digoxin controls rate but does not cardiovert AF to sinus rhythm.
D) Verapamil does not cardiovert AF; it controls ventricular rate only.
E) Sotalol is not first-line for cardioversion; more used for maintenance of sinus rhythm.
Q10. A 48-year-old man is found to have asymptomatic AF on routine ECG. He has no other cardiac history, is normotensive, non-diabetic, and has no prior stroke. CHA₂DS₂-VA score is 0. What is the correct management regarding anticoagulation?
A) Start apixaban 5 mg BD
B) Start aspirin 75 mg daily
C) Anticoagulation not recommended
D) Start warfarin with INR 2–3
E) Start dabigatran 110 mg BD
B) Start aspirin 75 mg daily
C) Anticoagulation not recommended
D) Start warfarin with INR 2–3
E) Start dabigatran 110 mg BD
Answer: C — CHA₂DS₂-VA score 0 in a male — stroke risk is very low; anticoagulation is not recommended.
Distractors:
A) Apixaban carries bleeding risk that outweighs benefit at CHA₂DS₂-VA score 0.
B) Aspirin is not recommended for AF stroke prevention in 2024 ESC guidelines.
D) Warfarin is an anticoagulant; equally not indicated at this low-risk score.
E) Dabigatran is contraindicated without sufficient stroke risk to justify anticoagulation.
Distractors:
A) Apixaban carries bleeding risk that outweighs benefit at CHA₂DS₂-VA score 0.
B) Aspirin is not recommended for AF stroke prevention in 2024 ESC guidelines.
D) Warfarin is an anticoagulant; equally not indicated at this low-risk score.
E) Dabigatran is contraindicated without sufficient stroke risk to justify anticoagulation.
SVT & WPW (Q11–15)
Q11. A 28-year-old woman presents with sudden-onset palpitations for 20 minutes. BP 120/75 mmHg. ECG shows a regular narrow-complex tachycardia at 175 bpm, no visible P waves. Valsalva manoeuvre fails. What is the next step?
A) IV verapamil 5 mg
B) IV adenosine 6 mg rapid push
C) Synchronised DC cardioversion
D) IV metoprolol 5 mg
E) Oral diltiazem
B) IV adenosine 6 mg rapid push
C) Synchronised DC cardioversion
D) IV metoprolol 5 mg
E) Oral diltiazem
Answer: B — Adenosine 6 mg IV is first-line for haemodynamically stable AVNRT after vagal manoeuvres fail.
Distractors:
A) Verapamil is an alternative but adenosine is preferred as it is shorter-acting and first-line.
C) DC cardioversion is reserved for haemodynamically unstable SVT.
D) IV metoprolol can terminate SVT but is second-line after adenosine.
E) Oral diltiazem is too slow-acting for acute SVT termination.
Distractors:
A) Verapamil is an alternative but adenosine is preferred as it is shorter-acting and first-line.
C) DC cardioversion is reserved for haemodynamically unstable SVT.
D) IV metoprolol can terminate SVT but is second-line after adenosine.
E) Oral diltiazem is too slow-acting for acute SVT termination.
Q12. A 22-year-old man with known WPW syndrome presents with palpitations. ECG shows a regular narrow-complex tachycardia at 180 bpm consistent with orthodromic AVRT. He is haemodynamically stable. What is appropriate treatment?
A) IV adenosine 6 mg
B) IV flecainide
C) IV verapamil
D) Immediate DC cardioversion
E) IV amiodarone
B) IV flecainide
C) IV verapamil
D) Immediate DC cardioversion
E) IV amiodarone
Answer: A — Orthodromic AVRT uses AV node antegradely; adenosine safely terminates it by blocking the AV node.
Distractors:
B) Flecainide is used for antidromic AVRT or AF with WPW; unnecessary for narrow-complex AVRT.
C) Verapamil is acceptable alternative but adenosine is preferred first-line in WPW-AVRT.
D) DC cardioversion is unnecessary in haemodynamically stable narrow-complex AVRT.
E) Amiodarone is reserved if other measures fail; not first-line in stable orthodromic AVRT.
Distractors:
B) Flecainide is used for antidromic AVRT or AF with WPW; unnecessary for narrow-complex AVRT.
C) Verapamil is acceptable alternative but adenosine is preferred first-line in WPW-AVRT.
D) DC cardioversion is unnecessary in haemodynamically stable narrow-complex AVRT.
E) Amiodarone is reserved if other measures fail; not first-line in stable orthodromic AVRT.
Q13. A 35-year-old man collapses. ECG shows an irregular broad-complex tachycardia at 220 bpm with varying QRS morphology and delta waves. BP is 70/40 mmHg. Diagnosis?
A) Ventricular tachycardia
B) AF with aberrant conduction
C) Pre-excited AF (AF with WPW)
D) Polymorphic VT
E) Sinus tachycardia with LBBB
B) AF with aberrant conduction
C) Pre-excited AF (AF with WPW)
D) Polymorphic VT
E) Sinus tachycardia with LBBB
Answer: C — Irregular broad-complex tachycardia with delta waves in haemodynamic compromise = pre-excited AF (WPW + AF).
Distractors:
A) VT is typically regular with monomorphic QRS; lacks delta waves.
B) AF with aberrant conduction has typical LBBB/RBBB morphology, not delta waves.
D) Polymorphic VT (TdP) has characteristic twisting axis without pre-excitation features.
E) Sinus tachycardia with LBBB is regular; does not produce irregular broad-complex rhythm.
Distractors:
A) VT is typically regular with monomorphic QRS; lacks delta waves.
B) AF with aberrant conduction has typical LBBB/RBBB morphology, not delta waves.
D) Polymorphic VT (TdP) has characteristic twisting axis without pre-excitation features.
E) Sinus tachycardia with LBBB is regular; does not produce irregular broad-complex rhythm.
Q14. Following Q13: The patient is haemodynamically unstable. What is the most appropriate immediate treatment?
A) IV adenosine 12 mg
B) IV verapamil 5 mg
C) IV digoxin
D) Immediate unsynchronised DC shock
E) IV amiodarone 300 mg
B) IV verapamil 5 mg
C) IV digoxin
D) Immediate unsynchronised DC shock
E) IV amiodarone 300 mg
Answer: D — Haemodynamically unstable pre-excited AF requires immediate unsynchronised (or synchronised) DC cardioversion.
Distractors:
A) Adenosine blocks AV node, accelerates accessory pathway conduction in WPW+AF — can precipitate VF.
B) Verapamil blocks AV node similarly, potentially lethal in pre-excited AF.
C) Digoxin enhances accessory pathway conduction — absolutely contraindicated in WPW+AF.
E) Amiodarone has AV nodal blocking properties; less safe than immediate cardioversion here.
Distractors:
A) Adenosine blocks AV node, accelerates accessory pathway conduction in WPW+AF — can precipitate VF.
B) Verapamil blocks AV node similarly, potentially lethal in pre-excited AF.
C) Digoxin enhances accessory pathway conduction — absolutely contraindicated in WPW+AF.
E) Amiodarone has AV nodal blocking properties; less safe than immediate cardioversion here.
Q15. A 30-year-old woman is incidentally found to have a short PR interval and delta wave on a routine ECG. She is completely asymptomatic. What is the most appropriate next step?
A) Immediate electrophysiology study and ablation
B) Start propranolol prophylaxis
C) Refer to electrophysiology for risk stratification
D) No further action required
E) 24-hour Holter monitor only
B) Start propranolol prophylaxis
C) Refer to electrophysiology for risk stratification
D) No further action required
E) 24-hour Holter monitor only
Answer: C — Asymptomatic WPW requires EP risk stratification to assess for inducible arrhythmias and SCD risk.
Distractors:
A) Immediate ablation without prior risk stratification is not indicated for asymptomatic WPW.
B) Beta-blockers are not standard prophylaxis in asymptomatic WPW without documented arrhythmia.
D) No action may miss high-risk accessory pathways with short refractory period.
E) Holter alone does not assess accessory pathway refractory period or VF risk.
Distractors:
A) Immediate ablation without prior risk stratification is not indicated for asymptomatic WPW.
B) Beta-blockers are not standard prophylaxis in asymptomatic WPW without documented arrhythmia.
D) No action may miss high-risk accessory pathways with short refractory period.
E) Holter alone does not assess accessory pathway refractory period or VF risk.
VENTRICULAR TACHYCARDIA & TORSADES (Q16–22)
Q16. A 65-year-old man with prior MI presents with sustained palpitations. ECG shows a regular broad-complex tachycardia at 160 bpm. AV dissociation is present. BP 100/65 mmHg. What is the diagnosis?
A) SVT with LBBB aberrancy
B) Accelerated idioventricular rhythm
C) Ventricular tachycardia
D) AF with aberrant conduction
E) Antidromic AVRT
B) Accelerated idioventricular rhythm
C) Ventricular tachycardia
D) AF with aberrant conduction
E) Antidromic AVRT
Answer: C — AV dissociation in broad-complex tachycardia with ischaemic heart disease history confirms VT.
Distractors:
A) SVT with LBBB may mimic VT but AV dissociation is diagnostic of VT.
B) AIVR is typically slow (60–100 bpm); not tachycardic at 160 bpm.
D) AF is irregular; does not produce regular broad-complex tachycardia with AV dissociation.
E) Antidromic AVRT is regular but lacks AV dissociation; delta waves may be present.
Distractors:
A) SVT with LBBB may mimic VT but AV dissociation is diagnostic of VT.
B) AIVR is typically slow (60–100 bpm); not tachycardic at 160 bpm.
D) AF is irregular; does not produce regular broad-complex tachycardia with AV dissociation.
E) Antidromic AVRT is regular but lacks AV dissociation; delta waves may be present.
Q17. A 70-year-old man with ischaemic cardiomyopathy (LVEF 25%) has recurrent monomorphic VT. He is haemodynamically stable. ECG confirms VT at 155 bpm. What is the most appropriate acute treatment?
A) IV adenosine 6 mg
B) Synchronised DC cardioversion immediately
C) IV amiodarone 150 mg over 10 minutes
D) IV lidocaine 1 mg/kg
E) IV verapamil 5 mg
B) Synchronised DC cardioversion immediately
C) IV amiodarone 150 mg over 10 minutes
D) IV lidocaine 1 mg/kg
E) IV verapamil 5 mg
Answer: C — IV amiodarone is first-line for haemodynamically stable monomorphic VT in structural heart disease.
Distractors:
A) Adenosine terminates AVNRT/AVRT; ineffective and potentially dangerous in VT.
B) DC cardioversion is appropriate but reserved for haemodynamically unstable or drug-refractory VT.
D) Lidocaine is an acceptable alternative but amiodarone is preferred in structural heart disease.
E) Verapamil can precipitate haemodynamic collapse in VT with structural heart disease — contraindicated.
Distractors:
A) Adenosine terminates AVNRT/AVRT; ineffective and potentially dangerous in VT.
B) DC cardioversion is appropriate but reserved for haemodynamically unstable or drug-refractory VT.
D) Lidocaine is an acceptable alternative but amiodarone is preferred in structural heart disease.
E) Verapamil can precipitate haemodynamic collapse in VT with structural heart disease — contraindicated.
Q18. A 55-year-old woman develops runs of polymorphic VT. ECG shows prolonged QTc of 560 ms, and VT has a twisting pattern around the isoelectric baseline. She is on haloperidol and sotalol. What is the immediate treatment?
A) IV amiodarone 300 mg
B) IV lidocaine 100 mg
C) Synchronised cardioversion
D) IV magnesium sulphate 2 g over 10 minutes
E) Oral beta-blocker
B) IV lidocaine 100 mg
C) Synchronised cardioversion
D) IV magnesium sulphate 2 g over 10 minutes
E) Oral beta-blocker
Answer: D — IV magnesium is first-line for torsades de pointes regardless of serum magnesium level.
Distractors:
A) Amiodarone further prolongs QT interval — contraindicated in torsades de pointes.
B) Lidocaine may suppress VT but magnesium is superior and specifically indicated for TdP.
C) Cardioversion may terminate acute episode but TdP recurs without removing precipitant.
E) Oral beta-blocker is too slow for acute treatment and may not adequately prevent recurrence.
Distractors:
A) Amiodarone further prolongs QT interval — contraindicated in torsades de pointes.
B) Lidocaine may suppress VT but magnesium is superior and specifically indicated for TdP.
C) Cardioversion may terminate acute episode but TdP recurs without removing precipitant.
E) Oral beta-blocker is too slow for acute treatment and may not adequately prevent recurrence.
Q19. Following Q18: What is the most important precipitating factor to address in this patient?
A) Add potassium supplementation only
B) Withhold haloperidol and sotalol immediately
C) Increase the sotalol dose
D) Add quinidine
E) Perform DC cardioversion to reset rhythm
B) Withhold haloperidol and sotalol immediately
C) Increase the sotalol dose
D) Add quinidine
E) Perform DC cardioversion to reset rhythm
Answer: B — Sotalol and haloperidol both prolong QT; immediate withdrawal is mandatory in drug-induced TdP.
Distractors:
A) Correcting hypokalaemia is important but insufficient without stopping QT-prolonging drugs.
C) Increasing sotalol worsens QT prolongation and further risks TdP recurrence.
D) Quinidine is a class Ia agent that prolongs QT — absolutely contraindicated in TdP.
E) DC cardioversion is not the primary intervention; drug withdrawal treats the cause.
Distractors:
A) Correcting hypokalaemia is important but insufficient without stopping QT-prolonging drugs.
C) Increasing sotalol worsens QT prolongation and further risks TdP recurrence.
D) Quinidine is a class Ia agent that prolongs QT — absolutely contraindicated in TdP.
E) DC cardioversion is not the primary intervention; drug withdrawal treats the cause.
Q20. A 48-year-old man with hypertrophic cardiomyopathy (LVEF 70%, septal thickness 22 mm) is resuscitated from out-of-hospital VF arrest. Post-resuscitation ECG shows sinus rhythm. What is the most important secondary prevention measure?
A) Oral amiodarone long-term
B) ICD implantation
C) Catheter ablation of VT focus
D) Beta-blocker therapy alone
E) Disopyramide
B) ICD implantation
C) Catheter ablation of VT focus
D) Beta-blocker therapy alone
E) Disopyramide
Answer: B — ICD is class I for secondary prevention of SCD following aborted VF/VT in HCM.
Distractors:
A) Amiodarone reduces VT burden but does not reliably prevent SCD; ICD is superior.
C) Ablation can reduce VT episodes but cannot replace ICD for SCD prevention post-arrest.
D) Beta-blockers are standard in HCM but insufficient as sole secondary prevention post-arrest.
E) Disopyramide reduces LVOT obstruction in HCM; it does not prevent SCD.
Distractors:
A) Amiodarone reduces VT burden but does not reliably prevent SCD; ICD is superior.
C) Ablation can reduce VT episodes but cannot replace ICD for SCD prevention post-arrest.
D) Beta-blockers are standard in HCM but insufficient as sole secondary prevention post-arrest.
E) Disopyramide reduces LVOT obstruction in HCM; it does not prevent SCD.
Q21. A 60-year-old man with LVEF 30% and prior MI develops VT storm (>3 sustained VT episodes in 24 hours) despite IV amiodarone. What is the next step?
A) Increase amiodarone infusion rate
B) Add IV lidocaine
C) Emergent catheter ablation
D) Implant ICD urgently
E) IV magnesium sulphate
B) Add IV lidocaine
C) Emergent catheter ablation
D) Implant ICD urgently
E) IV magnesium sulphate
Answer: C — Catheter ablation is recommended for drug-refractory VT storm in ischaemic cardiomyopathy.
Distractors:
A) Escalating amiodarone risks toxicity; standard doses are already maximised in VT storm.
B) Lidocaine can be added as bridging therapy but is not definitive for VT storm.
D) ICD prevents SCD but cannot terminate ongoing VT storm; ablation addresses the substrate.
E) Magnesium is indicated for TdP/polymorphic VT with long QT, not monomorphic VT storm.
Distractors:
A) Escalating amiodarone risks toxicity; standard doses are already maximised in VT storm.
B) Lidocaine can be added as bridging therapy but is not definitive for VT storm.
D) ICD prevents SCD but cannot terminate ongoing VT storm; ablation addresses the substrate.
E) Magnesium is indicated for TdP/polymorphic VT with long QT, not monomorphic VT storm.
Q22. A 25-year-old athlete collapses during exercise. ECG shows right bundle branch block pattern with ST elevation in V1–V3 (saddle-back morphology) — Brugada pattern. He is resuscitated. Family history reveals his brother died suddenly at age 30. What is indicated?
A) Oral quinidine alone
B) Catheter ablation only
C) ICD implantation
D) Amiodarone lifelong
E) Beta-blocker therapy
B) Catheter ablation only
C) ICD implantation
D) Amiodarone lifelong
E) Beta-blocker therapy
Answer: C — Symptomatic Brugada syndrome (aborted SCD) is a class I ICD indication.
Distractors:
A) Quinidine can suppress arrhythmias in Brugada but is not sufficient as sole therapy post-arrest.
B) Catheter ablation of epicardial substrate is emerging but not first-line post-arrest.
D) Amiodarone is ineffective in Brugada syndrome and may exacerbate the phenotype.
E) Beta-blockers have no role in Brugada syndrome and may unmask/worsen the phenotype.
Distractors:
A) Quinidine can suppress arrhythmias in Brugada but is not sufficient as sole therapy post-arrest.
B) Catheter ablation of epicardial substrate is emerging but not first-line post-arrest.
D) Amiodarone is ineffective in Brugada syndrome and may exacerbate the phenotype.
E) Beta-blockers have no role in Brugada syndrome and may unmask/worsen the phenotype.
AV BLOCKS (Q23–30)
Q23. A 72-year-old man has an ECG showing a PR interval of 240 ms, every P wave followed by a QRS, normal QRS duration. He is asymptomatic. What is the diagnosis and management?
A) Second-degree AV block Mobitz I — pace immediately
B) First-degree AV block — no treatment required
C) Second-degree AV block Mobitz II — urgent pacing
D) Third-degree AV block — urgent pacing
E) First-degree AV block — start atropine
B) First-degree AV block — no treatment required
C) Second-degree AV block Mobitz II — urgent pacing
D) Third-degree AV block — urgent pacing
E) First-degree AV block — start atropine
Answer: B — PR >200 ms with 1:1 AV conduction and normal QRS = first-degree AV block; no treatment needed.
Distractors:
A) Mobitz I has progressive PR prolongation before a dropped beat; not seen here.
C) Mobitz II has fixed PR with sudden dropped QRS; not consistent with this ECG.
D) Third-degree AV block has complete AV dissociation; all P waves are conducted here.
E) Atropine is not indicated for asymptomatic first-degree AV block.
Distractors:
A) Mobitz I has progressive PR prolongation before a dropped beat; not seen here.
C) Mobitz II has fixed PR with sudden dropped QRS; not consistent with this ECG.
D) Third-degree AV block has complete AV dissociation; all P waves are conducted here.
E) Atropine is not indicated for asymptomatic first-degree AV block.
Q24. A 65-year-old woman has an ECG showing progressive lengthening of PR interval over 3 beats, followed by a dropped QRS, then the cycle repeats. QRS duration is 90 ms. What is the diagnosis?
A) First-degree AV block
B) Second-degree AV block Mobitz type I (Wenckebach)
C) Second-degree AV block Mobitz type II
D) 2:1 AV block
E) Third-degree AV block
B) Second-degree AV block Mobitz type I (Wenckebach)
C) Second-degree AV block Mobitz type II
D) 2:1 AV block
E) Third-degree AV block
Answer: B — Progressive PR prolongation followed by a dropped beat = Mobitz I (Wenckebach); occurs at AV node level.
Distractors:
A) First-degree AV block has fixed prolonged PR with no dropped beats.
C) Mobitz II has fixed PR interval before a sudden dropped beat with no progressive prolongation.
D) 2:1 block has alternate P waves conducted; cannot distinguish Mobitz I from II without longer strip.
E) Third-degree AV block has complete dissociation with no conducted beats.
Distractors:
A) First-degree AV block has fixed prolonged PR with no dropped beats.
C) Mobitz II has fixed PR interval before a sudden dropped beat with no progressive prolongation.
D) 2:1 block has alternate P waves conducted; cannot distinguish Mobitz I from II without longer strip.
E) Third-degree AV block has complete dissociation with no conducted beats.
Q25. An 80-year-old man has episodes of near-syncope. ECG shows fixed PR interval of 180 ms with sudden 3:2 dropped QRS complexes (no PR prolongation before the dropped beat). QRS is 140 ms with RBBB morphology. What is the diagnosis and appropriate management?
A) Mobitz I — reassure and monitor
B) Mobitz II — urgent permanent pacemaker
C) First-degree AV block — no action
D) Third-degree AV block — atropine
E) Mobitz II — give atropine as bridging therapy
B) Mobitz II — urgent permanent pacemaker
C) First-degree AV block — no action
D) Third-degree AV block — atropine
E) Mobitz II — give atropine as bridging therapy
Answer: B — Mobitz II with wide QRS indicates infra-Hisian block; high risk of complete heart block — urgent PPM.
Distractors:
A) Mobitz I is a benign nodal block; Mobitz II with wide QRS is a high-risk infranodal lesion.
C) PR interval is normal; this is Mobitz II with wide QRS, not first-degree AV block.
D) Atropine has no effect on infranodal (Mobitz II) block and may paradoxically worsen it.
E) HKMLE trap: Atropine is ineffective and potentially harmful in Mobitz II — urgent pacing required.
Distractors:
A) Mobitz I is a benign nodal block; Mobitz II with wide QRS is a high-risk infranodal lesion.
C) PR interval is normal; this is Mobitz II with wide QRS, not first-degree AV block.
D) Atropine has no effect on infranodal (Mobitz II) block and may paradoxically worsen it.
E) HKMLE trap: Atropine is ineffective and potentially harmful in Mobitz II — urgent pacing required.
Q26. A 70-year-old man presents with syncope. ECG shows P waves at 72 bpm and QRS complexes at 38 bpm with no consistent relationship between them. QRS is wide. BP 85/60 mmHg. What is the most appropriate immediate treatment?
A) Atropine 0.5 mg IV
B) Temporary transvenous pacing
C) Oral theophylline
D) IV isoproterenol infusion
E) DC cardioversion
B) Temporary transvenous pacing
C) Oral theophylline
D) IV isoproterenol infusion
E) DC cardioversion
Answer: B — Complete (third-degree) AV block with haemodynamic compromise requires urgent temporary transvenous pacing.
Distractors:
A) Atropine works at AV nodal level; wide-QRS complete heart block is infranodal — atropine ineffective.
C) Oral theophylline is too slow and used for chronic management, not acute haemodynamic compromise.
D) Isoproterenol may provide temporary bridge but temporary pacing is definitive.
E) DC cardioversion treats tachyarrhythmias; complete heart block is a bradyarrhythmia.
Distractors:
A) Atropine works at AV nodal level; wide-QRS complete heart block is infranodal — atropine ineffective.
C) Oral theophylline is too slow and used for chronic management, not acute haemodynamic compromise.
D) Isoproterenol may provide temporary bridge but temporary pacing is definitive.
E) DC cardioversion treats tachyarrhythmias; complete heart block is a bradyarrhythmia.
Q27. A 55-year-old man presents 12 hours after inferior STEMI. ECG shows complete AV dissociation with narrow-QRS escape at 50 bpm. He is asymptomatic with BP 110/70 mmHg. What is the expected outcome?
A) Permanent pacemaker is immediately required
B) AV block will likely be permanent due to ischaemic damage
C) Block is usually transient — due to AV nodal ischaemia from RCA
D) Block indicates proximal LAD occlusion
E) LBBB is expected to develop concurrently
B) AV block will likely be permanent due to ischaemic damage
C) Block is usually transient — due to AV nodal ischaemia from RCA
D) Block indicates proximal LAD occlusion
E) LBBB is expected to develop concurrently
Answer: C — Inferior MI causes AV nodal ischaemia (RCA territory); complete AV block is usually transient, resolves 5–7 days.
Distractors:
A) Permanent pacing is rarely needed for inferior MI-related AV block; it usually resolves spontaneously.
B) Inferior MI AV block is typically reversible unlike anterior MI-associated infranodal block.
D) Inferior STEMI involves RCA; LAD supplies anterior wall and His-Purkinje system.
E) LBBB complicates anterior MI; inferior MI more commonly causes transient AV nodal block.
Distractors:
A) Permanent pacing is rarely needed for inferior MI-related AV block; it usually resolves spontaneously.
B) Inferior MI AV block is typically reversible unlike anterior MI-associated infranodal block.
D) Inferior STEMI involves RCA; LAD supplies anterior wall and His-Purkinje system.
E) LBBB complicates anterior MI; inferior MI more commonly causes transient AV nodal block.
Q28. A 60-year-old woman develops complete AV block following anterior STEMI. ECG shows wide-QRS escape at 28 bpm. What is the significance and management?
A) Transient — observe without pacing
B) Indicates infranodal necrosis — requires permanent pacemaker
C) Requires atropine 3 mg IV
D) Will resolve with thrombolysis
E) Treat with temporary pacing then reassess at 4 weeks
B) Indicates infranodal necrosis — requires permanent pacemaker
C) Requires atropine 3 mg IV
D) Will resolve with thrombolysis
E) Treat with temporary pacing then reassess at 4 weeks
Answer: B — Anterior MI causes infranodal (His-Purkinje) necrosis; complete AV block is usually permanent — PPM indicated.
Distractors:
A) Unlike inferior MI, anterior MI-related complete AV block rarely resolves spontaneously.
C) Atropine is ineffective for infranodal block; temporary then permanent pacing is required.
D) Thrombolysis may limit infarct extension but does not reverse established infranodal necrosis.
E) Temporary pacing is appropriate as bridge but permanent pacing is ultimately required.
Distractors:
A) Unlike inferior MI, anterior MI-related complete AV block rarely resolves spontaneously.
C) Atropine is ineffective for infranodal block; temporary then permanent pacing is required.
D) Thrombolysis may limit infarct extension but does not reverse established infranodal necrosis.
E) Temporary pacing is appropriate as bridge but permanent pacing is ultimately required.
Q29. An 88-year-old woman presents with falls and bradycardia (HR 32 bpm). ECG shows complete AV block with narrow-QRS junctional escape. She is on metoprolol 100 mg BD for hypertension. What is the first immediate step?
A) Implant a permanent pacemaker immediately
B) Stop metoprolol and reassess rhythm
C) Give atropine 3 mg IV
D) Temporary pacing immediately
E) Give isoprenaline infusion
B) Stop metoprolol and reassess rhythm
C) Give atropine 3 mg IV
D) Temporary pacing immediately
E) Give isoprenaline infusion
Answer: B — Reversible causes (beta-blocker excess) must be excluded before committing to permanent pacing.
Distractors:
A) Permanent pacing before excluding reversible drug cause is premature and potentially unnecessary.
C) Atropine may help narrow-QRS junctional block but withdrawing the causative drug is priority.
D) Temporary pacing may be needed if haemodynamically compromised but drug withdrawal is first.
E) Isoprenaline is rarely used and carries arrhythmia risk; drug withdrawal is more appropriate.
Distractors:
A) Permanent pacing before excluding reversible drug cause is premature and potentially unnecessary.
C) Atropine may help narrow-QRS junctional block but withdrawing the causative drug is priority.
D) Temporary pacing may be needed if haemodynamically compromised but drug withdrawal is first.
E) Isoprenaline is rarely used and carries arrhythmia risk; drug withdrawal is more appropriate.
Q30. A 75-year-old man has a 12-lead ECG showing right bundle branch block (RBBB) and left anterior fascicular block (LAFB) — bifascicular block. He has no symptoms and a normal LVEF. What is the management?
A) Prophylactic permanent pacemaker immediately
B) Urgent electrophysiology study
C) Reassure, monitor; no pacing unless symptomatic
D) Start amiodarone to prevent progression
E) Annual Holter monitoring only
B) Urgent electrophysiology study
C) Reassure, monitor; no pacing unless symptomatic
D) Start amiodarone to prevent progression
E) Annual Holter monitoring only
Answer: C — Asymptomatic bifascicular block does not require prophylactic pacing; risk of progression is low.
Distractors:
A) Prophylactic pacing is not indicated in asymptomatic bifascicular block with no syncope.
B) EPS is considered for symptomatic bifascicular block with syncope to assess for infranodal disease.
D) Amiodarone is not used for conduction system disease and may worsen AV block.
E) Holter may detect intermittent block but is not the primary management decision.
Distractors:
A) Prophylactic pacing is not indicated in asymptomatic bifascicular block with no syncope.
B) EPS is considered for symptomatic bifascicular block with syncope to assess for infranodal disease.
D) Amiodarone is not used for conduction system disease and may worsen AV block.
E) Holter may detect intermittent block but is not the primary management decision.
BUNDLE BRANCH BLOCK (Q31–32)
Q31. A 58-year-old man presents with chest pain. ECG shows LBBB that is new compared to a prior ECG 6 months ago. Troponin is mildly elevated. What is the correct management?
A) Reassure — new LBBB with chest pain is rarely ischaemic
B) Treat as STEMI equivalent — urgent coronary angiography
C) Perform exercise stress test
D) Start amiodarone
E) Rate-control with beta-blocker
B) Treat as STEMI equivalent — urgent coronary angiography
C) Perform exercise stress test
D) Start amiodarone
E) Rate-control with beta-blocker
Answer: B — New LBBB with chest pain and troponin rise is treated as STEMI equivalent — urgent reperfusion indicated.
Distractors:
A) New LBBB with ischaemic symptoms has significant diagnostic weight for anterior STEMI equivalent.
C) Stress testing is absolutely contraindicated in suspected acute coronary syndrome.
D) Amiodarone does not treat ischaemia and has no role in new LBBB due to MI.
E) Rate control is for AF/tachyarrhythmias; new LBBB with STEMI equivalent requires urgent PCI.
Distractors:
A) New LBBB with ischaemic symptoms has significant diagnostic weight for anterior STEMI equivalent.
C) Stress testing is absolutely contraindicated in suspected acute coronary syndrome.
D) Amiodarone does not treat ischaemia and has no role in new LBBB due to MI.
E) Rate control is for AF/tachyarrhythmias; new LBBB with STEMI equivalent requires urgent PCI.
Q32. A 72-year-old woman has LBBB on ECG, LVEF 25%, NYHA Class III HF despite optimal medical therapy. QRS duration is 165 ms. What device therapy is most appropriate?
A) ICD only
B) Permanent pacemaker
C) Cardiac resynchronisation therapy with defibrillator (CRT-D)
D) IV amiodarone
E) No device therapy — optimise medications first
B) Permanent pacemaker
C) Cardiac resynchronisation therapy with defibrillator (CRT-D)
D) IV amiodarone
E) No device therapy — optimise medications first
Answer: C — CRT-D is indicated in HFrEF (LVEF ≤35%) with LBBB morphology, QRS ≥150 ms, NYHA II–IV despite OMT.
Distractors:
A) ICD alone does not address dyssynchrony; CRT addresses mechanical dyssynchrony from LBBB.
B) Right ventricular pacing without biventricular pacing worsens dyssynchrony in HFrEF.
D) Amiodarone is not device therapy and does not treat mechanical dyssynchrony from LBBB.
E) LBBB with QRS 165 ms, LVEF 25%, and NYHA III — clear CRT-D indications are already met.
Distractors:
A) ICD alone does not address dyssynchrony; CRT addresses mechanical dyssynchrony from LBBB.
B) Right ventricular pacing without biventricular pacing worsens dyssynchrony in HFrEF.
D) Amiodarone is not device therapy and does not treat mechanical dyssynchrony from LBBB.
E) LBBB with QRS 165 ms, LVEF 25%, and NYHA III — clear CRT-D indications are already met.
CARDIAC ARREST (Q33–38)
Q33. A 55-year-old man collapses in the ED. No pulse, no spontaneous breathing. Monitor shows coarse ventricular fibrillation. What is the priority sequence?
A) Airway → IV adrenaline → defibrillation
B) CPR 2 minutes → check rhythm → defibrillate if VF
C) Defibrillate immediately → CPR if pulse not restored
D) IV amiodarone → defibrillate → CPR
E) Intubate first → CPR → defibrillate
B) CPR 2 minutes → check rhythm → defibrillate if VF
C) Defibrillate immediately → CPR if pulse not restored
D) IV amiodarone → defibrillate → CPR
E) Intubate first → CPR → defibrillate
Answer: C — For witnessed VF with immediately available defibrillator, immediate defibrillation before CPR cycles is appropriate.
Distractors:
A) Adrenaline is given after the first shock cycle; defibrillation has priority in witnessed VF.
B) CPR first is correct for unmonitored arrest; for monitored VF, immediate shock is the priority.
D) Amiodarone is given for shock-refractory VF after 3 shocks, not before first defibrillation.
E) Intubation is not the first priority; defibrillation in VF takes precedence over airway.
Distractors:
A) Adrenaline is given after the first shock cycle; defibrillation has priority in witnessed VF.
B) CPR first is correct for unmonitored arrest; for monitored VF, immediate shock is the priority.
D) Amiodarone is given for shock-refractory VF after 3 shocks, not before first defibrillation.
E) Intubation is not the first priority; defibrillation in VF takes precedence over airway.
Q34. A patient is in cardiac arrest. ECG shows organised electrical activity at 60 bpm but there is no pulse. What is this rhythm and the most important immediate assessment?
A) Asystole — give adrenaline 1 mg IV
B) VF — defibrillate immediately
C) PEA — assess for reversible 4 H's and 4 T's
D) Complete AV block — pace immediately
E) Sinus bradycardia — give atropine
B) VF — defibrillate immediately
C) PEA — assess for reversible 4 H's and 4 T's
D) Complete AV block — pace immediately
E) Sinus bradycardia — give atropine
Answer: C — PEA (pulseless electrical activity): organised ECG with no pulse — immediate search for reversible causes.
Distractors:
A) Asystole shows a flat or near-flat ECG line; PEA has organised electrical activity.
B) VF has chaotic, disorganised baseline; PEA has organised QRS complexes.
D) Complete heart block has AV dissociation; PEA can be any organised rhythm — focus on causes.
E) Sinus bradycardia with a pulse is not cardiac arrest; PEA requires CPR immediately.
Distractors:
A) Asystole shows a flat or near-flat ECG line; PEA has organised electrical activity.
B) VF has chaotic, disorganised baseline; PEA has organised QRS complexes.
D) Complete heart block has AV dissociation; PEA can be any organised rhythm — focus on causes.
E) Sinus bradycardia with a pulse is not cardiac arrest; PEA requires CPR immediately.
Q35. A 60-year-old woman is successfully resuscitated from out-of-hospital VF cardiac arrest. She remains unconscious (GCS 6). Temperature is 37.2°C. Post-ROSC ECG shows no ST changes. What is the management priority?
A) Immediate coronary angiography regardless of ECG
B) Targeted temperature management at 36–37.5°C and consider angiography based on clinical findings
C) Cool to 32–34°C for 24 hours (therapeutic hypothermia)
D) Immediate thrombolysis
E) Transfer to neuro ICU for seizure prophylaxis only
B) Targeted temperature management at 36–37.5°C and consider angiography based on clinical findings
C) Cool to 32–34°C for 24 hours (therapeutic hypothermia)
D) Immediate thrombolysis
E) Transfer to neuro ICU for seizure prophylaxis only
Answer: B — 2024 AHA/ESC: TTM at 36–37.5°C is recommended; routine immediate angiography without STEMI is no longer recommended.
Distractors:
A) HKMLE trap: ALPS/COACT trials show routine post-arrest PCI without STEMI does not improve outcomes.
C) Cooling to 32–34°C is no longer standard; 36°C is equivalent and easier to implement.
D) Thrombolysis is not indicated for VF arrest without confirmed acute PE or STEMI.
E) Seizure prophylaxis is important but TTM and haemodynamic stabilisation are the higher priorities.
Distractors:
A) HKMLE trap: ALPS/COACT trials show routine post-arrest PCI without STEMI does not improve outcomes.
C) Cooling to 32–34°C is no longer standard; 36°C is equivalent and easier to implement.
D) Thrombolysis is not indicated for VF arrest without confirmed acute PE or STEMI.
E) Seizure prophylaxis is important but TTM and haemodynamic stabilisation are the higher priorities.
Q36. A 45-year-old man is in VF cardiac arrest. After 3 shocks and 3 cycles of CPR, VF persists. Adrenaline has been given. What drug should be administered now?
A) IV atropine 3 mg
B) IV amiodarone 300 mg
C) IV magnesium 2 g
D) IV sodium bicarbonate 50 mL 8.4%
E) IV calcium gluconate 10 mL
B) IV amiodarone 300 mg
C) IV magnesium 2 g
D) IV sodium bicarbonate 50 mL 8.4%
E) IV calcium gluconate 10 mL
Answer: B — IV amiodarone 300 mg is given for shock-refractory VF/pulseless VT after 3 shocks.
Distractors:
A) Atropine is used for asystole/PEA with bradycardia; not indicated in VF management.
C) Magnesium is indicated for VF in hypomagnesaemia or torsades; not routine shock-refractory VF.
D) Sodium bicarbonate is reserved for confirmed severe acidosis or TCA overdose; not routine VF.
E) Calcium is used for hypocalcaemia, hyperkalaemia, or calcium channel blocker toxicity.
Distractors:
A) Atropine is used for asystole/PEA with bradycardia; not indicated in VF management.
C) Magnesium is indicated for VF in hypomagnesaemia or torsades; not routine shock-refractory VF.
D) Sodium bicarbonate is reserved for confirmed severe acidosis or TCA overdose; not routine VF.
E) Calcium is used for hypocalcaemia, hyperkalaemia, or calcium channel blocker toxicity.
Q37. A 70-year-old woman in asystolic cardiac arrest. CPR is ongoing. After 2 cycles of CPR and adrenaline 1 mg IV, rhythm remains asystole. What is the next drug intervention?
A) Atropine 3 mg IV
B) Second dose of adrenaline 1 mg IV every 3–5 minutes
C) Amiodarone 300 mg IV
D) Bicarbonate 50 mL
E) Vasopressin 40 units
B) Second dose of adrenaline 1 mg IV every 3–5 minutes
C) Amiodarone 300 mg IV
D) Bicarbonate 50 mL
E) Vasopressin 40 units
Answer: B — Adrenaline 1 mg IV every 3–5 minutes is standard in non-shockable rhythms (asystole/PEA).
Distractors:
A) Atropine is no longer recommended in ALS protocols for asystole; adrenaline is the drug of choice.
C) Amiodarone is only for shockable rhythms (VF/pVT); not indicated in asystole.
D) Bicarbonate is not routinely indicated; reserved for severe acidosis or toxin-induced arrest.
E) Vasopressin is not part of current ERC/AHA ALS algorithms; adrenaline is standard.
Distractors:
A) Atropine is no longer recommended in ALS protocols for asystole; adrenaline is the drug of choice.
C) Amiodarone is only for shockable rhythms (VF/pVT); not indicated in asystole.
D) Bicarbonate is not routinely indicated; reserved for severe acidosis or toxin-induced arrest.
E) Vasopressin is not part of current ERC/AHA ALS algorithms; adrenaline is standard.
Q38. A 52-year-old man is resuscitated after cardiac arrest with suspected PE as the cause (massive bilateral PEs seen on CTPA pre-arrest). PEA persists despite CPR and adrenaline. What additional intervention is appropriate?
A) IV amiodarone 300 mg
B) IV alteplase 50 mg over 2 minutes
C) Immediate surgical embolectomy
D) Heparin infusion
E) Increase CPR compression rate to 160/min
B) IV alteplase 50 mg over 2 minutes
C) Immediate surgical embolectomy
D) Heparin infusion
E) Increase CPR compression rate to 160/min
Answer: B — Thrombolysis (alteplase 50 mg) is recommended in confirmed PE-related cardiac arrest; CPR must continue for 60–90 minutes post-thrombolysis.
Distractors:
A) Amiodarone is for shockable VF/VT; ineffective against massive PE causing PEA.
C) Surgical embolectomy is not immediately feasible during active CPR; thrombolysis is first.
D) Unfractionated heparin alone is too slow to relieve acute massive PE during cardiac arrest.
E) Standard CPR rate is 100–120/min; increasing rate does not improve perfusion in PE.
Distractors:
A) Amiodarone is for shockable VF/VT; ineffective against massive PE causing PEA.
C) Surgical embolectomy is not immediately feasible during active CPR; thrombolysis is first.
D) Unfractionated heparin alone is too slow to relieve acute massive PE during cardiac arrest.
E) Standard CPR rate is 100–120/min; increasing rate does not improve perfusion in PE.
ACUTE PULMONARY OEDEMA (Q39–42)
Q39. A 70-year-old man with known LVEF 20% presents with acute breathlessness. RR 30/min, SpO₂ 84% on air. Bilateral basal crackles and fine crepitations to mid-zones. BP 170/100 mmHg. CXR: bat-wing shadowing, Kerley B lines. What is first-line management?
A) IV furosemide + CPAP/NIV + GTN infusion
B) IV morphine 4 mg + furosemide
C) IV dobutamine immediately
D) Urgent intubation and mechanical ventilation
E) Oral ramipril and furosemide
B) IV morphine 4 mg + furosemide
C) IV dobutamine immediately
D) Urgent intubation and mechanical ventilation
E) Oral ramipril and furosemide
Answer: A — Acute pulmonary oedema with hypertension: IV furosemide, CPAP/NIV, and nitrates (GTN) are first-line.
Distractors:
B) HKMLE trap: Morphine is no longer recommended in acute pulmonary oedema — ADHERE registry showed increased mortality.
C) Dobutamine is for cardiogenic shock with low cardiac output; contraindicated with hypertension (afterload concern).
D) Intubation is for refractory APO failing NIV; NIV is first-line and avoids intubation in most.
E) Oral medications are too slow for acute decompensation with hypoxia and severe symptoms.
Distractors:
B) HKMLE trap: Morphine is no longer recommended in acute pulmonary oedema — ADHERE registry showed increased mortality.
C) Dobutamine is for cardiogenic shock with low cardiac output; contraindicated with hypertension (afterload concern).
D) Intubation is for refractory APO failing NIV; NIV is first-line and avoids intubation in most.
E) Oral medications are too slow for acute decompensation with hypoxia and severe symptoms.
Q40. A 65-year-old woman with APO is given IV morphine 4 mg by the night doctor before guidelines were checked. She deteriorates — RR increases, SpO₂ drops to 78%. What is the problem with morphine in APO?
A) Morphine causes bronchospasm worsening hypoxia
B) Morphine increases sympathetic tone and raises BP
C) Morphine causes respiratory depression, increases ICU admission, and raises mortality
D) Morphine reduces preload excessively, causing hypotension
E) Morphine has no role in symptom relief only
B) Morphine increases sympathetic tone and raises BP
C) Morphine causes respiratory depression, increases ICU admission, and raises mortality
D) Morphine reduces preload excessively, causing hypotension
E) Morphine has no role in symptom relief only
Answer: C — ADHERE registry: morphine in APO associated with increased mechanical ventilation, ICU admission, and in-hospital mortality.
Distractors:
A) Morphine does not cause significant bronchospasm; respiratory depression is the main concern.
B) Morphine reduces sympathetic tone; the problem is respiratory depression, not sympathetic activation.
D) Preload reduction is a minor effect; the dominant harmful effect is respiratory depression.
E) This understates the issue — morphine has both symptom-relief and harmful respiratory effects.
Distractors:
A) Morphine does not cause significant bronchospasm; respiratory depression is the main concern.
B) Morphine reduces sympathetic tone; the problem is respiratory depression, not sympathetic activation.
D) Preload reduction is a minor effect; the dominant harmful effect is respiratory depression.
E) This understates the issue — morphine has both symptom-relief and harmful respiratory effects.
Q41. A 72-year-old man with APO has BP 80/50 mmHg despite IV furosemide and oxygen. SpO₂ 88% on CPAP. HR 120 bpm, cold peripheries. What is the most appropriate treatment?
A) IV GTN infusion
B) IV furosemide repeated
C) IV dobutamine + noradrenaline if needed
D) IV beta-blocker
E) IV morphine 4 mg
B) IV furosemide repeated
C) IV dobutamine + noradrenaline if needed
D) IV beta-blocker
E) IV morphine 4 mg
Answer: C — APO with cardiogenic shock (BP <90 mmHg, cold peripheries): inotropes ± vasopressors are indicated.
Distractors:
A) GTN causes vasodilation — contraindicated with systolic BP <90 mmHg due to risk of further hypotension.
B) Repeated furosemide causes further preload reduction, worsening hypotension in cardiogenic shock.
D) Beta-blockers are negatively inotropic — absolutely contraindicated in acute cardiogenic shock.
E) Morphine increases mortality in APO and would further depress respiration and cardiovascular function.
Distractors:
A) GTN causes vasodilation — contraindicated with systolic BP <90 mmHg due to risk of further hypotension.
B) Repeated furosemide causes further preload reduction, worsening hypotension in cardiogenic shock.
D) Beta-blockers are negatively inotropic — absolutely contraindicated in acute cardiogenic shock.
E) Morphine increases mortality in APO and would further depress respiration and cardiovascular function.
Q42. A 68-year-old woman with APO is treated with CPAP. What is the primary mechanism by which CPAP improves oxygenation in acute pulmonary oedema?
A) Reduces heart rate by vagal stimulation
B) Recruits collapsed alveoli and reduces intrapulmonary shunting
C) Directly reduces myocardial ischaemia
D) Reduces plasma BNP levels acutely
E) Increases pulmonary artery pressure
B) Recruits collapsed alveoli and reduces intrapulmonary shunting
C) Directly reduces myocardial ischaemia
D) Reduces plasma BNP levels acutely
E) Increases pulmonary artery pressure
Answer: B — CPAP increases functional residual capacity, recruits alveoli, reduces shunt, and improves oxygenation.
Distractors:
A) CPAP does not significantly modulate heart rate via vagal mechanism.
C) CPAP improves oxygenation but does not directly treat ischaemia; revascularisation addresses that.
D) BNP may decrease with treatment response but CPAP's primary mechanism is alveolar recruitment.
E) CPAP reduces — not increases — pulmonary artery pressure by improving oxygenation and reducing hypoxic vasoconstriction.
Distractors:
A) CPAP does not significantly modulate heart rate via vagal mechanism.
C) CPAP improves oxygenation but does not directly treat ischaemia; revascularisation addresses that.
D) BNP may decrease with treatment response but CPAP's primary mechanism is alveolar recruitment.
E) CPAP reduces — not increases — pulmonary artery pressure by improving oxygenation and reducing hypoxic vasoconstriction.
CARDIOGENIC SHOCK (Q43–45)
Q43. A 60-year-old man presents 3 hours after anterior STEMI. BP 75/40 mmHg, HR 120 bpm, urine output 10 mL/hr, cold extremities. Cardiac index 1.6 L/min/m². What is the diagnosis and first priority?
A) Distributive shock — start broad-spectrum antibiotics
B) Cardiogenic shock — urgent coronary angiography and PCI
C) Hypovolaemic shock — IV fluid challenge
D) Cardiogenic shock — start IV furosemide
E) Obstructive shock — bedside echo to exclude tamponade
B) Cardiogenic shock — urgent coronary angiography and PCI
C) Hypovolaemic shock — IV fluid challenge
D) Cardiogenic shock — start IV furosemide
E) Obstructive shock — bedside echo to exclude tamponade
Answer: B — Cardiogenic shock complicating anterior STEMI: immediate revascularisation (primary PCI) is the only treatment that improves survival.
Distractors:
A) Distributive shock (sepsis) presents with warm peripheries and vasoplegia; this is cold-periphery CS.
C) IV fluids in cardiogenic shock worsen pulmonary oedema without improving cardiac output.
D) Furosemide in hypotensive cardiogenic shock worsens preload and haemodynamics.
E) Echo is valuable but should not delay immediate coronary angiography in post-STEMI CS.
Distractors:
A) Distributive shock (sepsis) presents with warm peripheries and vasoplegia; this is cold-periphery CS.
C) IV fluids in cardiogenic shock worsen pulmonary oedema without improving cardiac output.
D) Furosemide in hypotensive cardiogenic shock worsens preload and haemodynamics.
E) Echo is valuable but should not delay immediate coronary angiography in post-STEMI CS.
Q44. A 58-year-old man with cardiogenic shock post-STEMI (BP 80/50 mmHg, CI 1.5 L/min/m²) has PCI performed but remains in shock despite noradrenaline. An intra-aortic balloon pump (IABP) is inserted. What is the mechanism of IABP benefit?
A) Increases heart rate and contractility
B) Inflates in systole to increase cardiac output
C) Deflates in systole to reduce afterload; inflates in diastole to augment coronary perfusion
D) Increases preload by peripheral vasoconstriction
E) Acts as a left ventricular assist device replacing cardiac output completely
B) Inflates in systole to increase cardiac output
C) Deflates in systole to reduce afterload; inflates in diastole to augment coronary perfusion
D) Increases preload by peripheral vasoconstriction
E) Acts as a left ventricular assist device replacing cardiac output completely
Answer: C — IABP: diastolic inflation augments coronary perfusion pressure; systolic deflation reduces LV afterload.
Distractors:
A) IABP does not increase heart rate; it modulates loading conditions and coronary perfusion.
B) IABP inflates in diastole (not systole) to augment diastolic coronary flow.
D) IABP reduces afterload via deflation in systole; it does not increase preload via vasoconstriction.
E) IABP augments cardiac output by ~0.5–1 L/min; it does not replace cardiac output.
Distractors:
A) IABP does not increase heart rate; it modulates loading conditions and coronary perfusion.
B) IABP inflates in diastole (not systole) to augment diastolic coronary flow.
D) IABP reduces afterload via deflation in systole; it does not increase preload via vasoconstriction.
E) IABP augments cardiac output by ~0.5–1 L/min; it does not replace cardiac output.
Q45. A 65-year-old man is in cardiogenic shock post-anterior STEMI. Despite PCI, dobutamine, and IABP, haemodynamics remain poor (MAP 55 mmHg, CI 1.3 L/min/m²). LVEF is 15%. What is the next escalation?
A) Add IV furosemide to offload the ventricle
B) Implant a percutaneous LVAD (Impella) or consider VA-ECMO
C) Start oral beta-blocker
D) Emergency CABG
E) IV amiodarone for arrhythmia suppression
B) Implant a percutaneous LVAD (Impella) or consider VA-ECMO
C) Start oral beta-blocker
D) Emergency CABG
E) IV amiodarone for arrhythmia suppression
Answer: B — Refractory cardiogenic shock with failing haemodynamics despite IABP — percutaneous LVAD (Impella) or VA-ECMO is the appropriate escalation.
Distractors:
A) Furosemide reduces preload; in cardiogenic shock with CI 1.3 this worsens forward flow.
C) Beta-blocker is negatively inotropic — absolutely contraindicated in active cardiogenic shock.
D) Emergency CABG in haemodynamic instability carries prohibitive risk; MCS stabilisation is needed first.
E) Amiodarone is for arrhythmia management; it does not address mechanical pump failure.
Distractors:
A) Furosemide reduces preload; in cardiogenic shock with CI 1.3 this worsens forward flow.
C) Beta-blocker is negatively inotropic — absolutely contraindicated in active cardiogenic shock.
D) Emergency CABG in haemodynamic instability carries prohibitive risk; MCS stabilisation is needed first.
E) Amiodarone is for arrhythmia management; it does not address mechanical pump failure.
CARDIAC TAMPONADE (Q46–48)
Q46. A 55-year-old woman with known malignant pericardial effusion presents with dyspnoea and near-syncope. BP 88/70 mmHg, HR 120 bpm. JVP is elevated. Heart sounds are muffled. BP drops by 18 mmHg on inspiration. ECG shows electrical alternans. What is the diagnosis?
A) Tension pneumothorax
B) Pulmonary embolism
C) Cardiac tamponade
D) Congestive cardiac failure
E) Aortic dissection
B) Pulmonary embolism
C) Cardiac tamponade
D) Congestive cardiac failure
E) Aortic dissection
Answer: C — Beck's triad (hypotension + muffled sounds + elevated JVP) + pulsus paradoxus >10 mmHg + electrical alternans = cardiac tamponade.
Distractors:
A) Tension pneumothorax causes deviated trachea, absent breath sounds; no electrical alternans.
B) PE presents with pleuritic pain, elevated JVP, but not muffled sounds or electrical alternans.
D) CCF has bilateral crepitations, S3 gallop; pulsus paradoxus and electrical alternans unusual.
E) Aortic dissection causes chest/back pain, pulse differentials; not pulsus paradoxus and alternans.
Distractors:
A) Tension pneumothorax causes deviated trachea, absent breath sounds; no electrical alternans.
B) PE presents with pleuritic pain, elevated JVP, but not muffled sounds or electrical alternans.
D) CCF has bilateral crepitations, S3 gallop; pulsus paradoxus and electrical alternans unusual.
E) Aortic dissection causes chest/back pain, pulse differentials; not pulsus paradoxus and alternans.
Q47. Following Q46: Bedside echo confirms large pericardial effusion with right ventricular diastolic collapse. BP is 80/60 mmHg. What is the definitive treatment?
A) IV furosemide to reduce pericardial fluid
B) IV noradrenaline to maintain BP while awaiting cardiology
C) Emergency pericardiocentesis
D) Emergency pericardial window surgery
E) IV fluid challenge to maintain filling pressures
B) IV noradrenaline to maintain BP while awaiting cardiology
C) Emergency pericardiocentesis
D) Emergency pericardial window surgery
E) IV fluid challenge to maintain filling pressures
Answer: C — Emergency pericardiocentesis is the definitive treatment for haemodynamically significant cardiac tamponade.
Distractors:
A) Furosemide reduces intravascular volume and worsens haemodynamics in tamponade.
B) Noradrenaline may temporise BP but does not relieve pericardial compression — pericardiocentesis is definitive.
D) Surgical window is appropriate for recurrent/loculated effusions; emergency pericardiocentesis is faster.
E) IV fluids may temporarily sustain filling but pericardiocentesis is required urgently.
Distractors:
A) Furosemide reduces intravascular volume and worsens haemodynamics in tamponade.
B) Noradrenaline may temporise BP but does not relieve pericardial compression — pericardiocentesis is definitive.
D) Surgical window is appropriate for recurrent/loculated effusions; emergency pericardiocentesis is faster.
E) IV fluids may temporarily sustain filling but pericardiocentesis is required urgently.
Q48. A 45-year-old woman undergoes emergency pericardiocentesis for tamponade. As the needle enters the pericardial space, ECG monitoring shows ST elevation and frequent PVCs. What does this indicate?
A) Successful drainage — proceed
B) The needle has contacted the myocardium — withdraw slightly
C) Haemorrhagic effusion — inject contrast
D) Ventricular fibrillation is imminent — shock immediately
E) Air in the pericardium — stop procedure
B) The needle has contacted the myocardium — withdraw slightly
C) Haemorrhagic effusion — inject contrast
D) Ventricular fibrillation is imminent — shock immediately
E) Air in the pericardium — stop procedure
Answer: B — ST elevation and PVCs during pericardiocentesis = needle touching the epicardium; withdraw the needle.
Distractors:
A) These ECG changes are not a sign of success; they indicate myocardial contact.
C) Contrast injection before confirming needle position risks myocardial injury.
D) VF requires treatment if it occurs, but the immediate action is to withdraw the needle first.
E) Pneumopericardium has different ECG features; ST changes + PVCs indicate epicardial contact.
Distractors:
A) These ECG changes are not a sign of success; they indicate myocardial contact.
C) Contrast injection before confirming needle position risks myocardial injury.
D) VF requires treatment if it occurs, but the immediate action is to withdraw the needle first.
E) Pneumopericardium has different ECG features; ST changes + PVCs indicate epicardial contact.
MIXED HIGH-YIELD HKMLE SCENARIOS (Q49–50)
Q49. A 78-year-old woman is brought in after a witnessed collapse. ECG shows atrial rate 80 bpm with no relationship to ventricular rate 28 bpm (wide QRS). She is on no medications. BP 60/40 mmHg. Following resuscitation and temporary pacing, her rhythm restores. Investigations show AV conduction normalises within 6 hours. She is found to have Lyme disease on serology. What is the management of the AV block?
A) Permanent pacemaker immediately
B) IV ceftriaxone for Lyme disease — AV block often resolves with antibiotics
C) Oral doxycycline only and reassess
D) Permanent pacemaker plus antibiotics
E) Long-term immunosuppression with steroids
B) IV ceftriaxone for Lyme disease — AV block often resolves with antibiotics
C) Oral doxycycline only and reassess
D) Permanent pacemaker plus antibiotics
E) Long-term immunosuppression with steroids
Answer: B — Lyme carditis causing complete AV block: IV ceftriaxone resolves AV block in the majority; permanent pacing is rarely required.
Distractors:
A) Permanent pacing is premature before treating the reversible infectious cause with antibiotics.
C) Oral doxycycline alone is insufficient for high-degree Lyme carditis; IV ceftriaxone is required.
D) Permanent pacemaker is rarely required in Lyme carditis; antibiotics are the definitive treatment.
E) Steroids are not standard for Lyme carditis; antibiotics are the primary treatment.
Distractors:
A) Permanent pacing is premature before treating the reversible infectious cause with antibiotics.
C) Oral doxycycline alone is insufficient for high-degree Lyme carditis; IV ceftriaxone is required.
D) Permanent pacemaker is rarely required in Lyme carditis; antibiotics are the definitive treatment.
E) Steroids are not standard for Lyme carditis; antibiotics are the primary treatment.
Q50. A 62-year-old man presents with central chest pain radiating to the jaw for 45 minutes. ECG shows ST elevation in leads II, III, aVF with complete AV block (wide-QRS escape at 30 bpm) and haemodynamic compromise. What is the correct sequence of management?
A) Atropine 3 mg IV → temporary pacing → delay PCI until stable
B) Temporary pacing → primary PCI → consider permanent pacemaker at 48 hours
C) Primary PCI urgently → temporary pacing if haemodynamic compromise persists post-PCI
D) Thrombolysis immediately → temporary pacing → assess for PCI
E) Atropine → amiodarone → PCI when AV block resolves
B) Temporary pacing → primary PCI → consider permanent pacemaker at 48 hours
C) Primary PCI urgently → temporary pacing if haemodynamic compromise persists post-PCI
D) Thrombolysis immediately → temporary pacing → assess for PCI
E) Atropine → amiodarone → PCI when AV block resolves
Answer: C — Inferior STEMI with complete AV block: primary PCI is urgent (treats both infarct and AV block); temporary pacing if required for haemodynamic support post-PCI.
Distractors:
A) Atropine is ineffective for wide-QRS infranodal block; delaying PCI increases infarct size and mortality.
B) Temporary pacing before PCI may delay revascularisation; PCI should not be delayed by pacing insertion.
D) Thrombolysis is inferior to primary PCI in this scenario and does not reliably resolve AV block.
E) Amiodarone has no role in AV block; the priority is coronary reperfusion by primary PCI.
Distractors:
A) Atropine is ineffective for wide-QRS infranodal block; delaying PCI increases infarct size and mortality.
B) Temporary pacing before PCI may delay revascularisation; PCI should not be delayed by pacing insertion.
D) Thrombolysis is inferior to primary PCI in this scenario and does not reliably resolve AV block.
E) Amiodarone has no role in AV block; the priority is coronary reperfusion by primary PCI.
Quick Reference: HKMLE Trap Summary
| Trap | Correct Answer |
|---|---|
| Adenosine in WPW + AF | Contraindicated — risks VF by forcing conduction down accessory pathway |
| Verapamil/Digoxin in WPW + AF | Contraindicated — AV nodal blockade accelerates accessory pathway |
| Atropine in Mobitz II (wide QRS) | Ineffective — infranodal block; can paradoxically worsen; urgent PPM |
| Morphine in acute pulmonary oedema | No longer recommended — ADHERE registry: increased mortality |
| GTN in APO with BP <90 mmHg | Contraindicated — worsens hypotension |
| Routine post-arrest PCI without STEMI | Not recommended (COACT/TOMAHAWK trials, 2024 AHA) |
| Beta-blocker in cardiogenic shock | Contraindicated — negatively inotropic |
| Furosemide in hypotensive cardiogenic shock | Harmful — reduces preload, worsens forward flow |
| Amiodarone in torsades de pointes | Contraindicated — prolongs QT further |
| Flecainide/Propafenone in structural heart disease | Contraindicated — pro-arrhythmic |
| IABP mechanism | Diastolic inflation (coronary perfusion) + systolic deflation (afterload reduction) |
| CHA₂DS₂-VA vs CHA₂DS₂-VASc | 2024 ESC replaced VASc with VA (sex removed as independent risk factor in males) |
Sources: Braunwald's Heart Disease; Goldman-Cecil Medicine; Fuster & Hurst's The Heart 15e; Tintinalli's Emergency Medicine; Harrison's Principles 22e (2025); 2024 ESC AF Guidelines (AF-CARE framework, CHA₂DS₂-VA); 2024 AHA Post-Cardiac Arrest Guidelines; ERC Resuscitation Guidelines.
Generate 50 HKMLE MCQs on Ischaemic Heart Disease and Heart Failure combined. Short clinical vignettes (1-2 sentences). Cover: stable angina, NSTEMI, STEMI, complications of MI, biomarkers, ECG changes, GDMT (beta-blocker, ACEi/ARNI, MRA, SGLT2i), acute decompensated HF, HFpEF vs HFrEF. For each question: - Correct answer + 10-word explanation - One 10-word explanation for each distractor Format: Q#. [Short vignette] A) B) C) D) E) Answer: X — [10 words] Distractors: A) [10 words] B) [10 words] C) [10 words] D) [10 words] E) [10 words] Include HKMLE trap answers: morphine in APO, IABP in CS without evidence, routine post-arrest PCI without STEMI, beta-blocker in acute decompensated HF. Base on Davidson's + 2024-2025 ESC/AHA guidelines. Now generate 50 MCQs.
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
ESC 2024 AHA 2025 heart failure guidelines GDMT SGLT2i ARNI HFpEF HFrEF updates
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.